scholarly journals Neurocognitive impairment in adolescent major depressive disorder: State vs. trait illness markers

2011 ◽  
Vol 133 (3) ◽  
pp. 625-632 ◽  
Author(s):  
Fadi T. Maalouf ◽  
David Brent ◽  
Luke Clark ◽  
Lucy Tavitian ◽  
Rebecca Munnell McHugh ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Neurocognitive Impairment ◽  
Major Depressive

Predictors of neurocognitive impairment at 2years after a first-episode major depressive disorder

2016 ◽  
Vol 68 ◽  
pp. 24-33 ◽  
Author(s):  
Chuan-zheng Gu ◽  
Hui-li He ◽  
Hui-feng Duan ◽  
Zhong-hua Su ◽  
Hong Chen ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Neurocognitive Impairment ◽  
First Episode ◽  
Major Depressive

Neurocognitive Impairment of Mental Rotation in Major Depressive Disorder

2014 ◽  
Vol 202 (8) ◽  
pp. 594-602 ◽  
Author(s):  
Jiu Chen ◽  
Wentao Ma ◽  
Yan Zhang ◽  
Lai-qi Yang ◽  
Zhijun Zhang ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Mental Rotation ◽  
Neurocognitive Impairment ◽  
Major Depressive

scholarly journals Association of Chemokine (C-C Motif) Receptor 5 and Ligand 5 with Recovery from Major Depressive Disorder and Related Neurocognitive Impairment

2021 ◽  
pp. 1-11
Author(s):  
Olivia Bauer ◽  
Vladimir M. Milenkovic ◽  
Sven Hilbert ◽  
Nina Sarubin ◽  
Johannes Weigl ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Executive Functions ◽  
Neuropsychological Test ◽  
Therapy Response ◽  
Response Prediction ◽  
Neurocognitive Impairment ◽  
Mrna Levels ◽  
Major Depressive ◽  
Emotional Perception

<b><i>Introduction:</i></b> Inflammatory processes play an important role in the pathophysiology of major depressive disorder (MDD), but their relevance for specific symptoms such as neurocognitive impairment is rarely investigated. <b><i>Methods:</i></b> In this observational study, we investigated the changes of leukocyte chemokine (C-C motif) receptor 5 (CCR5) and ligand 5 (CCL5) mRNA levels and inflammatory cytokines in 60 MDD patients before (PRE) and after 5 weeks (W5) of antidepressive treatment in relation to therapy response and alterations in cognitive functions by means of the Cambridge Neuropsychological Test Automated Battery (CANTAB). We hypothesized that elevated CCR5 and CCL5 levels in depressed patients would decrease upon treatment and could differ with regard to cognitive impairment associated with MDD. <b><i>Results:</i></b> Both CCR5 and CCL5 levels were significantly decreased in the responder group compared to nonresponders even before treatment. The cytokine IL-6 as a marker of inflammation in depression did not show a difference before treatment in future responders versus nonresponders, but decreased significantly upon antidepressive therapy. Regarding neurocognitive impairment in MDD patients, an increased misperception of the emotion “anger” after 5 weeks of treatment proved to be associated with a more pronounced change in CCR5, and the perception of the emotion “disgust” became faster along with a stronger decrease in CCL5 over the same time. Executive functions typically impaired in MDD patients were not markedly associated with alterations in CCR5/CCL5. <b><i>Discussion:</i></b> CCR5 and CCL5 are important in the targeting of immune cells by HIV. This is the first study providing valuable hints that both CCR5 and CCL5 might also serve as markers of therapy response prediction in MDD. Regarding neurocognitive impairment in depression, CCR5 and CCL5 did not reveal characteristic changes upon MDD treatment such as executive functions, which are probably delayed. However, changes of emotional perception appear to be an earlier responding feature.

scholarly journals Neurocognitive impairment in drug-free patients with major depressive disorder

2003 ◽  
Vol 182 (3) ◽  
pp. 214-220 ◽  
Author(s):  
Richard J. Porter ◽  
Peter Gallagher ◽  
Jill M. Thompson ◽  
Allan H. Young
Keyword(s):  
Major Depressive Disorder ◽  
Executive Function ◽  
Depressive Disorder ◽  
Learning And Memory ◽  
Psychotropic Medication ◽  
Memory Performance ◽  
Brain Dysfunction ◽  
Neurocognitive Impairment ◽  
Major Depressive ◽  
Severity Of Depression

BackgroundAlthough neurocognitive impairment has been widely reported in major depressive disorder (MDD), confounding factors, such as the effects of psychotropic medication, have rarely been controlled for.AimsTo examine neurocognitive function in medication-free patients with MDD and healthy controls.MethodForty-four patients meeting DSM–IV criteria for MDD, all psychotropic-medication-free for at least 6 weeks, and 44 demographically matched, healthy comparison subjects completed a comprehensive neurocognitive battery.ResultsPatients with depression were impaired significantly in a range of cognitive domains, including attention and executive function and visuospatial learning and memory, compared with controls. Motor and psychomotor functions were intact. Severity of depression correlated with learning and memory performance, but not executive function.ConclusionsPronounced neurocognitive impairment was found in this sample of young adult out-patients with MDD. This is not attributable to the confounding effects of psychotropic medication and could therefore provide an objective marker of brain dysfunction in depression.

Neurocognitive Impairment in Major Depressive Disorder

2015 ◽  
Vol 30 ◽  
pp. 1323
Author(s):  
J. Silva Ribeiro ◽  
A. Pestana Santos ◽  
L. Rosa ◽  
J. Amilcar
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Neurocognitive Impairment ◽  
Major Depressive
Sign in / Sign up

Export Citation Format

Share Document